Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

31. März 2026 08:45 ET | Quelle: Spherix Global Insights

PK Activation Gains Momentum in Thalassemia Agios’ Aqvesme Launch Reflects Strong Promise with Deliberate Uptake

Exton, PA, March 31, 2026 (GLOBE NEWSWIRE) -- Spherix Global Insights today announced new findings from Launch Dynamix™: Aqvesme in Thalassemia, highlighting early physician perceptions and adoption...
31. März 2026 08:45 ET | Quelle: Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting

PONTE VEDRA, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and...
31. März 2026 08:35 ET | Quelle: Ambros Therapeutics, Inc.

Ambros Therapeutics Announces Notice of Allowance for New U.S. Patent Application Covering Neridronate for Complex Regional Pain Syndrome Type 1

IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Ambros Therapeutics, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a new...
31. März 2026 08:30 ET | Quelle: Vantive

Vantive Presents New Data at WCN on How Coordinated Care Ecosystems Can Expand Home-Based Peritoneal Dialysis Access and Improve Patient Outcomes

Nephroprotection and early intervention support more planned dialysis starts, improved patient outcomes and increased use of home therapies, according to new studies. Real-world studies also evaluate...
31. März 2026 08:30 ET | Quelle: Tarsus Pharmaceuticals, Inc

Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

– A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission – IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus...
31. März 2026 08:30 ET | Quelle: Pelthos Therapeutics, Inc.

Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain

First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute ocular pain and chronic ocular surface pain commonly associated with dry eye disease CT2000 is a...
31. März 2026 08:30 ET | Quelle: PolyPid Ltd.

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

PolyPid Submits First Modules as Part of Rolling NDA Review; Completion expected in Second Quarter of 2026 U.S. Commercialization Partnership Negotiations on Track PETACH TIKVA, Israel, March 31,...
31. März 2026 08:05 ET | Quelle: INNOVATE Corp.

MediBeacon® Transdermal GFR Monitor and Reusable Sensor Receive CE Mark Under European Medical Device Regulation

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc. (“MediBeacon”), a medical technology company specializing...
31. März 2026 08:00 ET | Quelle: MediBeacon Inc.

MediBeacon® Transdermal GFR Monitor and Reusable Sensor Receive CE Mark Under European Medical Device Regulation

ST. LOUIS, March 31, 2026 (GLOBE NEWSWIRE) -- MediBeacon Inc., a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, today...
31. März 2026 08:00 ET | Quelle: Anathapindika Health LLC

Anathapindika Shines Spotlight on Detoxification During National Nutrition Month

Fort Lauderdale, FL, March 31, 2026 (GLOBE NEWSWIRE) -- March is National Nutrition Month. As part of the ongoing focus on nutrition, Anathapindika is shining a spotlight on the growing awareness...

Vorherige Seite

Nächste Seite